Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23850307 | 0.84 | RAB9A (0.36) | SMN1; SMN2KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL21835562 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EAPOBEC3AAPOBEC3GCYP1A2 | |
| SCHEMBL21835477 | 0.80 | SMN1; SMN2 (0.35) | SMN1; SMN2KDM4EAPOBEC3AAPOBEC3GCYP1A2 | |
| SCHEMBL13799632 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL21835462 | 0.73 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EAPOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL13799634 | 0.70 | HTT (0.40) | SMN1; SMN2KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL4163341 | 0.69 | CSNK2A1 (0.35) | SMN1; SMN2KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL25426461 | 0.68 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL23850118 | 0.68 | TOP2A (0.33) | SMN1; SMN2KDM4ERAB9ANPC1CYP1A2 | |
| SCHEMBL9276924 | 0.68 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4EAPOBEC3AAPOBEC3GKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033402-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| EP-3883573-A1 | MACROCYCLIC INHIBITORS OF DYRK1A | Dana-Farber Cancer Institute, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3856745-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | Dana Farber Cancer Institute, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020069118-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033402-A1 | MACROCYCLIC INHIBITORS OF ALK, TRKA, TRKB, AND ROS1 | ROS1, ALK, NTRK3 | SMN1; SMN2 1382/4885KDM4E 2318/4885APOBEC3A 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.